scholarly journals Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme

2006 ◽  
Vol 11 (5) ◽  
Author(s):  
M A R Bergsaker ◽  
B Feiring
Keyword(s):  
Conjugate Vaccine ◽  
Vaccination Programme ◽  
Pneumococcal Conjugate Vaccine ◽  
Childhood Vaccination ◽  
Routine Childhood

Pneumococcal conjugate vaccine is being added to the routine childhood vaccination programme in Norway, after a decision by the Norwegian government.

Routine childhood vaccination programme coverage, El Salvador, 2011—In search of timeliness

Vaccine ◽  
2014 ◽  
Vol 32 (4) ◽  
pp. 437-444 ◽  
Author(s):  
Eduardo Suárez-Castaneda ◽  
Lorenzo Pezzoli ◽  
Miguel Elas ◽  
Rafael Baltrons ◽  
Elner Osmin Crespin-Elías ◽  
...  
Keyword(s):  
El Salvador ◽  
Vaccination Programme ◽  
Childhood Vaccination ◽  
Routine Childhood ◽  
Programme Coverage

Bacterial Spectrum of Acute Otitis Media in Bulgarian Children during the 10-Valent Pneumococcal Conjugate Vaccine Era

2020 ◽  
Vol 15 (03) ◽  
pp. 135-143
Author(s):  
Lena Setchanova ◽  
Iglika Stancheva ◽  
Diana Popova ◽  
Alexandra Alexandrova ◽  
Ivan Mitov
Keyword(s):  
Streptococcus Pneumoniae ◽  
Otitis Media ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Acute Otitis Media ◽  
Childhood Vaccination ◽  
Middle Ear Fluid ◽  
High Prevalence ◽  
Culture Positive ◽  
Prevalent Pathogen

Abstract Objective The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in Bulgaria for universal childhood vaccination in 2010. The objective of this study was to describe bacterial pathogens responsible for acute otitis media (AOM) in children in the era of routine PCV10 immunization. Materials and Methods Middle ear fluid (MEF)/otorrhea or nasopharyngeal specimens were collected between May 2012 and April 2017 from 425 children aged < 12 years diagnosed with AOM; 71.5% of them were vaccinated. Capsular types of Streptococcus pneumoniae and Haemophilus influenzae and antimicrobial nonsusceptibility were determined. Results Among 240 children with “severe” AOM, the studied specimens were MEF/otorrhea, and a total of 132 (55.0%) children were culture-positive. The most frequently identified bacteria were S. pyоgenes (31.1%), followed by Staphylococcus aureus (21.2%), S. pneumoniae (20.4%), and nontypeable H. influenzae (12.1%). Among 185 nasopharyngeal specimens obtained from children at the onset of a “mild” AOM episode, 67.0% were culture-positive for otopathogens. The most common pathogens were S. pneumoniae (41.9%), followed by H. influenzae (25.8%), Moraxella catarrhalis (23.4%), and S. pyоgenes (14.5%), alone or in combinations. Among children with pneumococcal AOM (79), PCV10 serotypes (VTs) were 21.5%. A high prevalence (50%) of nonvaccine serotypes 3 (14), 19A (11), and 6C (7) was found among vaccinated children. Rates of nonsusceptibility of S. pneumoniae to penicillin, amoxicillin and erythromycin, and of multidrug resistance, were 51.2, 10.1, 51.2, and 51.2, respectively. The rate of ampicillin-non-susceptibility in H. influenzae was 25%. All M. catarrhalis isolates were β-lactamase producers, and 32.2% of S. pyogenes were erythromycin-resistant. Conclusion Following implementation of PCV10, S. pyogenes was the most prevalent pathogen in children with “severe” AOM. Numbers of S. pneumoniae recovered from MEF/otorrhea significantly decreased, as did the overall proportion of VTs among AOM patients. Streptococcus pneumoniae, H. influenzae, and M. catarrhalis were the most commonly found pathogens in the nasopharynx of children with less severe AOM episodes.

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

The Lancet ◽  
2007 ◽  
Vol 369 (9568) ◽  
pp. 1179-1186 ◽  
Author(s):  
Carlos G Grijalva ◽  
J Pekka Nuorti ◽  
Patrick G Arbogast ◽  
Stacey W Martin ◽  
Kathryn M Edwards ◽  
...  
Keyword(s):  
Time Series ◽  
Time Series Analysis ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Childhood Immunisation ◽  
Series Analysis ◽  
Routine Childhood ◽  
The Usa

scholarly journals Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1123
Author(s):  
Kristiana Alexandrova Nikolova ◽  
Mikael Andersson ◽  
Hans-Christian Slotved ◽  
Anders Koch
Keyword(s):  
Incidence Rate ◽  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
The Elderly ◽  
Incidence Rates ◽  
National Registry ◽  
Childhood Vaccination ◽  
Vaccination Program

The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 to the childhood vaccination program in Greenland. This study aimed to estimate the effectiveness of the PCV13 on the incidence of invasive pneumococcal disease (IPD) in children and in adults in Greenland. IPD cases from the pre-PCV13 period (January 1995–September 2010) were compared with the post-PCV13 period (September 2010–October 2020). Register data were collected from laboratory records, IPD reports, the national registry on admissions, and medical files. A total of 295 IPD cases were identified in the study period. Overall IPD incidence rate (IR) declined from the pre-PCV13 period to the post-PCV13 period (IR 23.3 to 15.3 per 100,000 person years). Overall IPD incidence among children decreased significantly, whereas overall IPD incidence among the elderly increased significantly. During the post-PCV13 period, the incidence of vaccine serotype (VT) IPD decreased in all ages, while the incidence of non-vaccine serotype (NVT) IPD increased. This increase was most substantial among elderly ≥60 years. In conclusion, the PCV13 has reduced incidence rates of IPD in Greenland. However, the increase in NVT IPD among the elderly is noteworthy, and sup-ports continued surveillance of IPD in the population of Greenland.

scholarly journals Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007

2009 ◽  
Vol 14 (12) ◽  
Author(s):  
H De Carvalho Gomes ◽  
M Muscat ◽  
D L Monnet ◽  
J Giesecke ◽  
P L Lopalco
Keyword(s):  
Conjugate Vaccine ◽  
Vaccination Programme ◽  
Pneumococcal Vaccine ◽  
Age Groups ◽  
Pneumococcal Vaccination ◽  
European Countries ◽  
Vaccine Uptake ◽  
Childhood Vaccination ◽  
Vaccine Introduction ◽  
National Vaccination Programme

The first pneumococcal vaccine targeting the youngest age groups, a seven-valent conjugate vaccine (PCV7), was licensed in Europe in 2001. Since then several European countries have introduced PCV7 in their childhood vaccination schedules. Still, information on vaccination schemes, vaccine uptake and impact of vaccine introduction is scarce in Europe. The following article summarises the characteristics of national pneumococcal vaccination programmes for children in 32 European countries and provides an estimate of vaccine use based on sales data for 22 countries between 2001 and 2007. There were wide variations in the recommended PCV7 vaccination schemes and in PCV7 use. High vaccine uptake was not always related to the presence of a national vaccination programme.

Sign in / Sign up

Export Citation Format

Share Document